News Article,Video

Maple Grove Medical Device Company Pioneers New Treatment For Prostate Cancer

June 18, 2020

Francis Medical Research Team

CCX Media visited Francis Medical, Wednesday, June 17, 2020 for exclusive interviews with CEO and President, Mike Kujak, and Founder and CTO, Michael Hoey.

Their two-minute video includes an explanation of our revolutionary water vapor therapy, as well as plans for the future, including our VAPOR 1 clinical study.

Click for Full Article

Share this post

Recent Posts

Francis Medical Announces Further Expansion of Commercial Vanquish® Procedures to Ablate Prostate Tissue

May 6th, 2026|

Minneapolis [May 06, 2026] – Francis Medical, Inc., a privately held medical device company based in Maple Grove, Minn., today announced that Naveen Kella, MD, of The Urology Place has successfully completed the first commercial procedures in San Antonio, Texas, using the Vanquish® Water Vapor Ablation System, a minimally invasive technology designed to ablate targeted prostate tissue. Dr. Kella, who was also a clinical investigator in the VAPOR 2 pivotal study, performed the procedures on patients diagnosed with localized prostate cancer at Huebner Ambulatory Surgery Center.

Francis Medical Announces First Commercial Vanquish® Procedure to Ablate Prostate Tissue in the Midwest

April 21st, 2026|

Minneapolis [April 21, 2026] – Francis Medical, Inc., a privately held medical device company based out of Maple Grove, MN, today announced that Aaron Milbank, MD. of Minnesota Urology has successfully completed the first commercial procedure in the Midwest using the Vanquish® Water Vapor Ablation System, a minimally invasive technology designed to ablate targeted prostate tissue.

Francis Medical Announces Further Commercial Expansion of Vanquish® Water Vapor Ablation with First Commercial Procedures to Ablate Targeted Prostate Tissue in the Southeast

April 16th, 2026|

Minneapolis, MN [April 16, 2026] – Francis Medical, Inc., a privately held medical device company, today announced the continued expansion of its U.S. commercial launch with the first commercial procedures performed using the Vanquish® Water Vapor Ablation System in the Southeast, a minimally invasive technology designed to ablate targeted prostate tissue.